| abstract |
The present invention relates to compounds of formula I, HetAr is a five- or six-membered heteroaryl selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and if When two R 1 appear, they can be the same or different; R 2 is lower alkyl or its single or multiple deuterated derivatives, lower alkyl substituted by halogen or lower alkoxy, unsubstituted or substituted by halogen Lower alkenyl, unsubstituted or halogen-substituted cycloalkyl or CH 2 -cycloalkyl, unsubstituted or lower alkyl substituted heterocycloalkyl or CH 2 -heterocycloalkyl; R 3 is halogen, lower Alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(O) 2 -lower alkyl; n is 1, 2 or 3; if n is >1, then R 3 may be the same or different; or relate to its pharmaceutically active acid addition salts, its racemic mixtures or its corresponding enantiomers and/or optical isomers and/or stereoisomers. The compounds can be used to treat Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D), multi-infarct dementia, boxer dementia or Down syndrome. |